Sulfasalazine-induced immune thrombocytopenia.

Authors
Category Primary study
JournalPostgraduate medical journal
Year 2007
Sulfasalazine is a well established disease-modifying anti-rheumatic drug commonly used in the treatment of rheumatic disorders and inflammatory bowel disease. Sulfasalazine was generally well tolerated in clinical trials, the most frequently reported adverse effects being adverse gastrointestinal effects, headache, dizziness and rash; myelosuppression can also occur. We are now reporting the first case of autoimmune thrombocytosis following sulfasalazine treatment.
Epistemonikos ID: 19fc27a426f400053e4f3e1b121b9a062c67eb83
First added on: Feb 15, 2022